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Aims Right ventricular (RV) lead placement can be contraindicated in patients after tricuspid valve (TV) surgery.
Placement of the implantable cardiac-defibrillator (ICD) lead in the middle cardiac vein (MCV) can be a viable op-
tion in these patients who have an indication for biventricular (BiV) ICD. We aim to describe the case of two
patients with MCV lead placement and provide a comprehensive review of patients with complex TV pathology
and indications for RV lead placement.
...................................................................................................................................................................................................
Methods
and results
We describe the cases of two patients with TV pathology unsuitable for the standard transvenous or surgical RV
lead placement and undergoing BiV ICD implantation. Their characteristics, procedure, and outcomes are summa-
rized. The BiV ICD was successfully placed with the RV lead positioned in the MCV in both patients. The proce-
dures had no complications and were well-tolerated. On follow-up, both patients had appropriate tachytherapy
with no readmissions for heart failure or worsening of cardiac function.
...................................................................................................................................................................................................
Conclusion Right ventricular lead placement of BiV ICD in the MCV can be an excellent alternative in patients with significant
TV pathology and poor surgical candidacy.
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Introduction
Implantable cardiac-defibrillators (ICDs) are indicated for primary
prevention in patients at high risk for ventricular tachycardia (VT) or
ventricular fibrillation (VF). They are also indicated for secondary
prevention of sudden cardiac death (SCD) in patients with prior sus-
tained VT/VF.1 Patients with heart failure, severely reduced left ven-
tricular (LV) function [ejection fraction (EF) < 35%], and wide QRS
on 12-lead electrocardiogram [ECG; QRS complex > 120 ms for left
bundle branch block and > 150 ms for right bundle branch block
(RBBB)] may benefit from cardiac resynchronization therapy (CRT)
as well as from the tachytherapy provided by ICDs and they usually
receive biventricular (BiV) ICD as part of their heart failure
therapy.2,3
Lead placement of the defibrillator coil near the right ventricular
(RV) apex is the recommended position for the RV ICD lead.4 This
becomes increasingly complicated in patients with tricuspid valve
(TV) pathology, such as patients with a mechanical TV. For
these patients, surgical epicardial system placement becomes the
conventional approach if their surgical risks permit. The implantation
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of dual-chamber ICD devices using the middle cardiac vein (MCV)
for six patients who were considered high risk for cardiac surgery
had been previously described.5 These patients had the defibrillator
coil placed in the MCV, and bipolar leads for sensing/pacing purposes
were placed in one of the coronary sinus branches.
Our literature review to date reveals scarce data describing trans-
venous implantation of BiV ICD using the MCV in patients with com-
plex TV pathology who are poor surgical candidates for epicardial
placement. We describe the case of two patients with BiV ICD im-
plantation with the utilization of that ICD lead placed in the MCV for
both pace and sense function.
Methods
Two patients at two institutions were evaluated and deemed candidates
for BiV ICD implantation. Both patients had significant TV pathology
preventing ICD lead placement through the TV and were also deemed
high risk for surgical epicardial lead placement.
The first patient is a 24-year-old woman who was found to have
methicillin-resistant Staphylococcus aureus endocarditis of both mitral and
TVs. She underwent mechanical replacement of both tricuspid and mitral
valves. At the time of surgery, her course was complicated by complete
heart block and subsequent placement of a dual-chamber permanent
pacemaker. The right ventricular lead was placed epicardially; the right
atrial lead was later implanted endocardially using an active fixation lead.
During her stay in the long-term acute rehab facility, she was noted to
have episodes of polymorphic VT in the setting of loss of RV lead capture
from rise in the pacing threshold (Figure 1). QTc was noted to be mildly
prolonged which was attributed to both bradycardia and treatment with
fluoroquinolone. She was deemed to be a poor candidate for implanta-
tion of new epicardial RV lead. Therefore, the dual-chamber pacemaker
system was upgraded to BiV pacemaker with implantation of a quadripo-
lar lead in the anterolateral branch of the coronary sinus for pacing. The
quadripolar lead was chosen to allow multiple choices for pacing in this
young patient with limited pacing options in the future. The sensing func-
tion of the epicardial RV lead was adequate with no evidence for noise.
Two weeks later, she suffered another cardiac arrest (VF) while at the
rehabilitation facility. Her electrocardiogram showed significant prolonga-
tion of QTc with no clear aetiology. Implantable cardiac-defibrillator im-
plantation was necessary. Thoracotomy was deemed to be a high-risk
procedure and the patient failed subcutaneous ICD screening. A single-
coil DF4 ICD lead with active fixation (St Jude Medical) was then
implanted in the MCV (Figure 2A–F). The helix was not extended. The
ICD lead provided adequate sensing and pacing function. Sensing and
tachytherapy pacing were programmed through the ICD lead. However,
pacing for the bradytherapy was mainly done through the previously
implanted quadripolar lead (mono-LV pacing) due to multiple excellent
options and preserved LV function. The leads were connected to BiV
ICD pulse generator. Defibrillation was successful at 15 J. The patient
What’s new?
• Endovascular placement of biventricular implantable cardiac-
defibrillator system might be still indicated in patients with tri-
cuspid valve (TV)-related contraindication due to no other
alternatives at this point.
• Implantable cardiac-defibrillator lead implantation through the
middle cardiac vein is a safe and adequate alternative for
patients with TV pathology precluding the traditional transve-
nous right ventricular lead implantation and not a candidate
for the surgical or subcutaneous option.
Figure 1 EKG demonstrating rise in threshold and loss of capture leading to cardiac arrest.
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tolerated the procedure well. Of note, genetic testing revealed a muta-
tion in KCNQ (long QT-1 syndrome).
The second patient was a 75-year-old man with a history of paroxys-
mal atrial fibrillation and coronary artery bypass graft surgery with con-
comitant bioprosthetic mitral and TV replacements. He has severe
valvular and peri-valvular regurgitation of his bioprosthetic TV (Figure 3).
He has had multiple admissions for heart failure with rapid progressive
worsening BiV function (last EF 25%). He also required blood transfusions
for haemolytic anaemia likely related to his TV pathology. His ECG was
remarkable for significant first-degree atrioventricular block with a very
wide RBBB (Figure 4). A heart catheterization revealed patent grafts with
no indication for coronary revascularization. Given the patient’s signifi-
cant tricuspid valvopathy epicardial BiV ICD system placement was con-
sidered. He was found to be a poor candidate for repeat thoracotomy
and a transvenous BiV ICD system approach was pursued. There was se-
rious concern that placement of the lead in the RV would worsen his
valvular or perivalvular regurgitation. For this reason, it was elected to
place the RV ICD lead in the MCV, and the helix was extended (Figure 5A
and B). The procedure was well-tolerated and without any complications.
Defibrillation was successful at 20 J and the patient was on amiodarone.
Results
Both procedures were successful and performed in the electrophysi-
ology lab under moderate sedation and local anaesthesia. There
were no peri-procedural complications. On follow-up, there was no
lead dislodgement or worsening ventricular function. Both leads in
the MCV have acceptable sensing, impedance, and pacing thresholds
(Table 1).
The first patient is currently 43months post-BiV ICD implantation.
She has received successful ICD shock therapy twice for VF. Her LV
function continues to be normal. The second patient’s clinical course
has improved dramatically. He is currently 25months post his BiV
ICD implantation. His New York Heart Association Classification has
improved fromClass III-IV to Class II symptoms. Furthermore, he has
had no heart failure-related readmissions since implantation of the
BiV ICD and haemoglobin has remained stable since implantation and
received appropriate, effective antitachycardia pacing.
Discussion
Cardiac resynchronization therapy in patients with heart failure, se-
vere LV systolic dysfunction, and wide QRS has been shown to im-
prove functional class, improve 6-min walking distance, reduce heart
failure admissions, reduce all-cause mortality, and in some instances
promote reverse remodelling.6–8 Many patients requiring CRT also
Figure 2 (A) Access to the coronary sinus was obtained using a
guiding sheath (CPS DirectTM SLII 115). The arrow is pointed to the
middle cardiac vein. (B) An inner catheter with a small injection of
contrast helped to guide a Glide wire to the middle cardiac vein. (C)
The delivery sheath was advanced deep into the middle cardiac vein
over the guiding wire. (D) A single-coil DF4 ICD lead with active fix-
ation (SJM 7122Q) was then placed in the middle cardiac vein. (E)
Chest X-ray, posterior-anterior view showing MCV lead placement
of the ICD. (F) Chest X-ray, lateral view showing MCV lead place-
ment of the ICD. ICD, implantable cardiac-defibrillator. MCV, mid-
dle cardiac vein.
Figure 3 Transoesophageal echocardiogram revealing biopros-
thetic tricuspid valve with severe valvular and peri-valvular
regurgitation.
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have indications for ICD placement.9 Implantable cardiac-defibrillator
is also indicated for secondary prevention of SCD in patients with
prior sustained VT/VF.1 Despite the benefits provided by BiV ICDs
patients may have complex TV pathology (such as prior TV repair or
replacement) with a relative or absolute contraindication to lead
placement through the TV. It should be completely avoided in
patients with mechanical TV. A transvenous approach is preferred
over the epicardial one.10 A prior retrospective study showed that
RV lead placement across a repaired TV was associated with recur-
rence of significant TV regurgitation and increase in late mortalities.11
Figure 4 Electrocardiogram showing the baseline prolonged PR segment and wide right bundle branch block.
Figure 5 (A) Chest X-ray, posterior-anterior view showing MCV lead placement of the ICD. (B) Chest X-ray, lateral view showing MCV lead
placement of the ICD. ICD, implantable cardiac-defibrillator. MCV, middle cardiac vein.
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Lead-induced TV dysfunctionmay be due to obstruction, perforation,
laceration, or lead entrapment.12 However, worse outcomes were
not seen in those with normally functioning bioprosthetic TV in an-
other small retrospective study.13 The patients in our study had bio-
prosthetic TVs with severe valvular and perivalvular regurgitation
precluding the addition of an RV ICD lead. We demonstrate that the
placement of the RV ICD lead in the MCV may be an acceptable al-
ternative to the standard approach for patients requiring BiV ICD.
A previous case review conducted by Lopez5 summarized the
safety and efficacy of ICD coil placement in the MCV in six individuals
as an alternative to epicardial placement via thoracotomy in patients
for whom RV lead placement was not possible. Of the six individuals,
four had TV replacement similar to our patients. All patients were
deemed to be poor surgical candidates. None of the patients under-
went BiV ICD implantation. Five of the six patients in that series re-
ceived another bipolar lead to do the pace/sense portion instead of
using the ICD lead (that was placed in the MCV). Four patients had
the lead placed in a lateral coronary sinus branch, and one patient
with Epstein anomaly had the lead placed in the atrialized portion of
the RV. This was done as a safety precaution since the patient had an
indication for ventricular pacing (brady/tachytherapy). Only one pa-
tient in that series had no indication for pacing and the same ICD lead
was used for sensing with an acceptable threshold. The helix was not
extended in the six patients in that series due to concern about per-
foration and effusion. They used dual-coil leads. We used single-coils
ICD and we used it in the sense/pace therapy in our patients and the
helix was extended in one patient with no issues. In the first patient, it
was felt that extending the helix was not needed. There was a con-
cern for possible pericardial effusion if the helix was extended due to
small body habitus (<50 kg) and chronic anticoagulation (double me-
chanical valve) with no immediate indication for BiV pacing, while we
feel it is most likely safe to extend the helix in such patients, that
decision needs to be based on a case by case approach. Although
dual-coil ICDs were more common until recent years, current data
suggest that these are not superior to single coil ICDs. Furthermore,
single-lead coils are associated with less complications including risk
of lead fracture, removal, and infection, and should be considered be-
fore implantation of dual-coil ICDs.14,15 DFT was successful in our
two cases, as well as, all six patients mentioned in the case series by
Lopez.5 Similar results have been noted in prior animal studies and it
should be considered that DFT testing to confirm appropriate sens-
ing may be lower than that for the standard RV lead.16
Grimard et al.17 described a case of a patient with TV prosthesis
and permanent atrial fibrillation requiring intermittent pacing and
ICD therapy. A floating coil in the inferior vena cava and a bipolar LV
lead was used. In our cases, we can use a bipolar lead in the septal po-
sition (MCV or great cardiac vein), floating coil, and DF1-IS4 system
rather than an ICD in the MCV. This can be a helpful approach in
patients with small MCVs. It can also provide another option for the
septal pacing (i.e. the great cardiac vein) if sensing or pacing thresh-
olds were poor in the MCV. However, it is important to minimize
the number of leads in young and smaller patients like our first.
New technologies like subcutaneous ICD and His pacing were suc-
cessfully used in some patients with TV disease. Subcutaneous ICD
placement, which eliminates the need for lead placement across TV,
can be ideal alternative for patients with TV disease if they passed the
subcutaneous ICD screening, and have no indication for pacing or
pacing was achieved with prior epicardial pacemaker or through LV
pacing.18,19 His pacing was done successfully in nine patients with TV
ring.20 While combining such technologies can be an excellent alter-
native for patients with an indication for BiV ICD they cannot be used
in patients similar to ours.
To our knowledge, this is the first report in the literature of
BiV ICD implantation with the utilization of that ICD lead placed
in the MCV for the pace/sense function. The beneficial long-term
outcomes and absence of complications are promising and
provide another strategy in similar high-risk patients with no other
alternatives.
Conclusions
In patients with significant TV pathology preventing ICD lead place-
ment in the RV, with indications for BiV ICD and poor surgical candi-
dacy, RV lead placement in the MCV can be an excellent alternative.
Conflict of interest:None declared.
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